Caribou Biosciences, Inc.: profit or loss including noncontrolling interests
Profit or loss including noncontrolling interests for Caribou Biosciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Caribou Biosciences, Inc. financial histories
What this measure means
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
Exact concept: us-gaap:ProfitLoss. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Reading these values
This selected numerical history matches Net income or loss for the same reporting intervals and original units. The accounting definitions remain distinct. Equal values do not establish that the concepts are interchangeable or explain why they match; filing dates and accessions may differ. Compare the definitions and source filings before combining them.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -148,125,000 | USD | 2026-03-05 | 10-K · 0001619856-26-000008 |
| 2024-01-01 | 2024-12-31 | -149,105,000 | USD | 2026-03-05 | 10-K · 0001619856-26-000008 |
| 2023-01-01 | 2023-12-31 | -102,070,000 | USD | 2025-03-10 | 10-K · 0001619856-25-000015 |
| 2022-01-01 | 2022-12-31 | -99,421,000 | USD | 2024-03-11 | 10-K · 0001619856-24-000013 |
| 2021-01-01 | 2021-12-31 | -66,923,000 | USD | 2023-03-09 | 10-K · 0001619856-23-000037 |
| 2020-01-01 | 2020-12-31 | -34,308,000 | USD | 2022-03-21 | 10-K · 0000950170-22-004233 |
| 2019-01-01 | 2019-12-31 | -23,431,000 | USD | 2022-03-21 | 10-K · 0000950170-22-004233 |
Related financial histories
- Caribou Biosciences, Inc.: total assets
- Caribou Biosciences, Inc.: total liabilities
- Caribou Biosciences, Inc.: stockholders equity
- Caribou Biosciences, Inc.: cash and cash equivalents
- Caribou Biosciences, Inc.: net income or loss
- Caribou Biosciences, Inc.: operating cash flow
- Caribou Biosciences, Inc.: capital expenditure payments
- Caribou Biosciences, Inc.: contract revenue excluding tax
- Caribou Biosciences, Inc.: financing cash flow
- Caribou Biosciences, Inc.: investing cash flow
- Caribou Biosciences, Inc.: retained earnings or deficit
- Caribou Biosciences, Inc.: basic weighted-average shares
- Caribou Biosciences, Inc.: diluted weighted-average shares
- Caribou Biosciences, Inc.: basic earnings per share
- Caribou Biosciences, Inc.: diluted earnings per share
- Caribou Biosciences, Inc.: income tax expense or benefit
- Caribou Biosciences, Inc.: net property, plant and equipment
- Caribou Biosciences, Inc.: share-based compensation expense
- Caribou Biosciences, Inc.: operating income or loss
- Caribou Biosciences, Inc.: current assets
- Caribou Biosciences, Inc.: interest expense
- Caribou Biosciences, Inc.: current liabilities
- Caribou Biosciences, Inc.: current accounts payable
- Caribou Biosciences, Inc.: net current accounts receivable
- Caribou Biosciences, Inc.: operating expenses
- Caribou Biosciences, Inc.: research and development expense
- Caribou Biosciences, Inc.: common shares outstanding
- Caribou Biosciences, Inc.: cash including restricted cash
- Caribou Biosciences, Inc.: additional paid-in capital
- Caribou Biosciences, Inc.: accumulated other comprehensive income or loss
- Caribou Biosciences, Inc.: operating lease right-of-use asset
- Caribou Biosciences, Inc.: operating lease liability
- Caribou Biosciences, Inc.: gross property, plant and equipment
- Caribou Biosciences, Inc.: accumulated depreciation on property, plant and equipment
- Caribou Biosciences, Inc.: other noncurrent assets
- Caribou Biosciences, Inc.: accrued current liabilities
- Caribou Biosciences, Inc.: prepaid expenses and other current assets
- Caribou Biosciences, Inc.: current contract liabilities
- Caribou Biosciences, Inc.: net deferred tax assets
- Caribou Biosciences, Inc.: net deferred tax liabilities
- Caribou Biosciences, Inc.: pre-tax income or loss from continuing operations
- Caribou Biosciences, Inc.: comprehensive income or loss
- Caribou Biosciences, Inc.: general and administrative expense
- Caribou Biosciences, Inc.: depreciation, depletion and amortization
- Caribou Biosciences, Inc.: nonoperating income or expense
- Caribou Biosciences, Inc.: current income tax expense or benefit
- Caribou Biosciences, Inc.: deferred income tax expense or benefit
- Caribou Biosciences, Inc.: income taxes paid, net
- Caribou Biosciences, Inc.: proceeds from issuing common stock
- Caribou Biosciences, Inc.: operating lease payments
- Caribou Biosciences, Inc.: change in accounts receivable
- Caribou Biosciences, Inc.: change in accounts payable
Inspect the source
- Entity
- Caribou Biosciences, Inc. / CIK 0001619856
- Captured
- 2026-09-21T17:20:42.928Z
- SEC response SHA-256
674cba4755e35dd8dffc48c6e0cce1da57694421900f490c9b675b483b710872
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001619856.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))